(:BBI)

Dec 01, 2023 05:00 pm ET
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today that its special meeting of stockholders (the “Special Meeting”), which was previously adjourned on November 16, 2023, has been adjourned for a second...
Nov 17, 2023 08:30 am ET
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, November 30, 2023 at 10 a.m. Mountain Time with...
Nov 13, 2023 08:30 am ET
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “Following the approval by our Board of a plan of...
Sep 19, 2023 04:01 pm ET
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX) today announced that, after conducting an extensive potential strategic alternatives process and careful consideration of the outcomes of this, its Board of Directors...
Aug 11, 2023 04:01 pm ET
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of...
Jul 21, 2023 08:00 am ET
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of...
May 10, 2023 04:01 pm ET
Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of...
Mar 30, 2023 04:01 pm ET
Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of...
Mar 07, 2023 04:01 pm ET
Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02
Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the...
Jan 27, 2023 08:00 am ET
Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer
Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the...
Jan 11, 2023 08:00 am ET
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity
Fresh Tracks Therapeutics, Inc. (“Fresh Tracks” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the...
Nov 10, 2022 04:05 pm ET
Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of...
Nov 03, 2022 04:05 pm ET
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription...
Sep 13, 2022 08:00 am ET
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
Fresh Tracks Therapeutics, Inc. (“FRTX” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for the treatment of...
Sep 07, 2022 08:00 am ET
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI) today announced that it has changed its name to Fresh Tracks Therapeutics, Inc. (“FRTX” or the “Company”). The new name, logo, website, and branding elements were introduced to reflect the company’s...
Aug 11, 2022 04:05 pm ET
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
Aug 02, 2022 04:05 pm ET
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and...
Jul 20, 2022 08:00 am ET
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and...
Jul 06, 2022 08:00 am ET
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
Jul 01, 2022 02:02 pm ET
Brickell Biotech Announces 1-For-45 Reverse Stock Split
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
May 19, 2022 08:00 am ET
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
May 17, 2022 10:53 am ET
Healthcare Breakthroughs: IDRA, NMLSF, LMLLF, BBI; Life Sciences Leaders Report Latest Advances in Novel Therapeutics for Autism, Oncology, Autoimmune Diseases, and Glaucoma
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Brickell Biotech (NASDAQ: BBI), Idera Pharmaceuticals...
May 12, 2022 04:01 pm ET
Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
May 05, 2022 04:01 pm ET
Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
May 04, 2022 10:53 am ET
BioMed Momentum: NMLSF, BBI, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for Autism, COVID-19, Oncology, and Glaucoma
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Veru Inc. (NASDAQ: VERU), PharmaDrug (OTC: LMLLF) (CSE:...
May 04, 2022 09:31 am ET
Thinking about buying stock in Immutep, Brickell Biotech, Indonesia Energy, TG Therapeutics, or Aquestive Therapeutics?
NEW YORK, May 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMP, BBI, INDO, TGTX, and AQST.
May 03, 2022 04:02 pm ET
Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”) announced today that its 2022 annual meeting of stockholders (the “Annual Meeting”) has been adjourned to Tuesday, May 17, 2022 at 10 a.m. Mountain Time with respect to all proposals described in...
May 03, 2022 04:01 pm ET
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or “Company”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
Apr 19, 2022 11:05 am ET
Thinking about buying stock in Toughbuilt Industries, Camber Energy, Hallador Energy, Brickell Biotech, or Cassava Sciences?
NEW YORK, April 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, CEI, HNRG, BBI, and SAVA.
Apr 19, 2022 09:53 am ET
Healthcare Breakthroughs: AGRX, NMLSF, BBI, LMLLF; BioMed Leaders Report Latest Advances in New Drug Development for Women’s Health, Autism, Glaucoma, and Cancer Therapeutics
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Brickell Biotech (NASDAQ: BBI), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Agile Therapeutics...
Mar 15, 2022 07:30 am ET
Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
Mar 10, 2022 08:00 am ET
Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
Mar 08, 2022 04:05 pm ET
Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
Feb 02, 2022 07:30 am ET
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune,...
Jan 19, 2022 10:46 am ET
Thinking about buying stock in Vinco Ventures, Brickell Biotech, Vale SA, Opendoor Technologies, or Bakkt?
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, BBI, VALE, OPEN, and BKKT.
Jan 18, 2022 09:55 am ET
Thinking about buying stock in Brickell Biotech, Zynga, 22nd Century Group, Nikola Corp, or Marathon Oil?
NEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBI, ZNGA, XXII, NKLA, and MRO.
Nov 09, 2021 04:05 pm ET
Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic,...
Nov 01, 2021 04:05 pm ET
Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and...
Oct 28, 2021 07:58 am ET
Brickell Biotech Prices Public Offering of Common Stock
Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and...
Oct 27, 2021 04:32 pm ET
Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock
Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and...
Oct 07, 2021 10:45 am ET
Thinking about buying stock in Camber Energy, Bit Digital, Brickell Biotech, Osmotica Pharmaceuticals, or SmileDirectClub?
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, BTBT, BBI, OSMT, and SDC.
Oct 07, 2021 06:55 am ET
Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance on all Primary and Secondary Endpoints, from Both U.S. Phase 3 Pivotal Clinical Studies of Sofpironium Bromide G
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and...
Sep 17, 2021 08:00 am ET
Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and...
Sep 08, 2021 08:30 am ET
Brickell Biotech to Participate at Upcoming September Conferences
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and...
Sep 01, 2021 07:05 am ET
Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic,...
Sep 01, 2021 07:00 am ET
Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic,...
Aug 16, 2021 08:00 am ET
Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Aug 12, 2021 04:01 pm ET
Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Jul 29, 2021 08:00 am ET
Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that it will...
Jul 22, 2021 04:05 pm ET
Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares
Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Jul 19, 2021 10:44 pm ET
Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million
Brickell Biotech, Inc. (Nasdaq: BBI) (the “Company” or “Brickell”), clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced...
Jul 19, 2021 05:25 pm ET
Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock
Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” or the “Company”), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Jul 06, 2021 08:00 am ET
Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its...
Jun 30, 2021 08:30 am ET
Thinking about buying stock in Vertex Energy, Exela Technologies, Bridgeline Digital, Verb Technology, or Brickell Biotech?
NEW YORK, June 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTNR, XELA, BLIN, VERB, and BBI.
Jun 29, 2021 04:05 pm ET
Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Ge
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Jun 24, 2021 08:00 am ET
Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Jun 01, 2021 08:00 am ET
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the...
May 13, 2021 04:01 pm ET
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Apr 29, 2021 08:00 am ET
Brickell Biotech to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13, 2021
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will...
Apr 27, 2021 07:30 am ET
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Apr 23, 2021 10:01 am ET
Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel as a Potential Treatment for Primary Axillary Hyperhidrosis
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Apr 16, 2021 10:00 am ET
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Apr 15, 2021 08:00 am ET
Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Mar 09, 2021 04:01 pm ET
Brickell Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Mar 05, 2021 08:00 am ET
Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will...
Feb 25, 2021 04:05 pm ET
Brickell Biotech to Participate in March Virtual Investor Conferences
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that Robert...
Feb 23, 2021 04:01 pm ET
Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will...
Feb 22, 2021 08:31 am ET
Thinking about buying stock in GameStop, Verb Technology, Brickell Biotech, Creative Realities, or Sorrento Therapeutics?
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, VERB, BBI, CREX, and SRNE.
Jan 19, 2021 07:00 am ET
Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the...
Dec 07, 2020 07:30 am ET
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced dosing of the...
Nov 18, 2020 07:00 am ET
Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its...
Nov 16, 2020 08:00 am ET
Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its...
Nov 12, 2020 04:01 pm ET
Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Oct 29, 2020 08:00 am ET
Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will...
Oct 22, 2020 08:00 pm ET
Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the pricing of...
Oct 06, 2020 07:00 am ET
Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today the...
Sep 25, 2020 07:00 am ET
Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that its...
Sep 10, 2020 04:05 pm ET
Brickell Biotech to Participate in September Virtual Investor Conferences
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its...
Sep 08, 2020 07:30 am ET
AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.
AnGes, Inc. (“AnGes”), announced today a collaboration agreement with Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, through which Brickell has the right to develop AnGes’ proprietary investigational...
Aug 31, 2020 04:05 pm ET
Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that Brickell...
Aug 12, 2020 04:01 pm ET
Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today...
Aug 03, 2020 04:05 pm ET
Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will...
Jun 17, 2020 10:00 pm ET
Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the pricing of...
Jun 15, 2020 06:30 am ET
Brickell Biotech Announces Positive Phase 3 Pivotal Study Results for Sofpironium Bromide in Japan Released by Development Partner, Kaken Pharmaceutical
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced the release of...
May 13, 2020 04:01 pm ET
Brickell Biotech Reports First Quarter 2020 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial...
May 04, 2020 04:05 pm ET
Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will...
Mar 18, 2020 04:01 pm ET
Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial...
Mar 09, 2020 04:05 pm ET
Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will...
Mar 04, 2020 06:30 am ET
Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that positive...
Feb 20, 2020 06:30 am ET
Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that positive...
Feb 18, 2020 06:30 am ET
Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements
Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin...
Jan 10, 2020 04:05 pm ET
Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its...
Nov 13, 2019 04:05 pm ET
Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial...
Oct 30, 2019 04:42 pm ET
Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest
Brickell Biotech, Inc. (“Brickell”) (NASDAQ: BBI), a clinical-stage pharmaceutical company, today announced that it has initiated an arbitration proceeding pursuant to Article 9 of the License Agreement previously entered into between Bodor...
Sep 03, 2019 06:45 am ET
Brickell Biotech Completes Merger with Vical
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, today announced the completion of its merger with Vical Incorporated (“Vical”), following approval by Vical’s stockholders. Brickell is expected to commence...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.